2002
Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial
Cushman M, Costantino J, Bovill E, Wickerham D, Buckley L, Roberts J, Krag D. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. British Journal Of Haematology 2002, 120: 109-116. PMID: 12492585, DOI: 10.1046/j.1365-2141.2003.03976.x.Peer-Reviewed Original ResearchConceptsBreast Cancer Prevention TrialVenous thrombosis risk factorsActivated protein CEffects of tamoxifenCancer Prevention TrialThrombosis risk factorsRisk factorsProtein CProtein SVenous thrombosisTamoxifen reduces breast cancer incidenceIncreased riskIncreased risk of venous thrombosisPrevention trialsActivated protein C resistanceRisk of venous thrombosisPlacebo-treated womenReduction of antithrombinTamoxifen-treated womenDouble-blind fashionMonths of treatmentActivated protein C ratioBreast cancer incidenceProtein C antigenBody mass index
2001
Tamoxifen and Cardiac Risk Factors in Healthy Women
Cushman M, Costantino J, Tracy R, Song K, Buckley L, Roberts J, Krag D. Tamoxifen and Cardiac Risk Factors in Healthy Women. Arteriosclerosis Thrombosis And Vascular Biology 2001, 21: 255-261. PMID: 11156862, DOI: 10.1161/01.atv.21.2.255.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnti-Inflammatory AgentsAntineoplastic Agents, HormonalBlood CoagulationBreast NeoplasmsC-Reactive ProteinCardiovascular DiseasesCardiovascular SystemCholesterolDouble-Blind MethodFemaleFibrinogenHumansPlacebosPostmenopauseRisk FactorsSelective Estrogen Receptor ModulatorsTamoxifenConceptsEffects of tamoxifenBreast Cancer Prevention TrialIncidence of breast cancerCardiovascular disease risk factorsHigh waist-to-hip ratioWaist-to-hip ratioHealthy womenDisease risk factorsRisk factorsCancer Prevention TrialAssociated with venous thrombosisFactor VII coagulant activityAssociation of tamoxifenFactors related to inflammationEffects of oral tamoxifenCardiac risk factorsC-reactive proteinVII coagulant activitySecondary analysisPrevention trialsMedian fibrinogenOral tamoxifenPostmenopausal womenPostmenopausal estrogenVenous thrombosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply